One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy is a research paper published in Frontiers in Cardiovascular Medicine (2024). On theSindex it has a DataRank of 0. It has been cited 16 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NHLBI NIH HHS
Grant: R01 HL168059
NHLBI NIH HHS
Grant: F32 HL160067
NHLBI NIH HHS
Grant: K08 HL143185
NHLBI NIH HHS
Grant: K08 HL167699
NHLBI NIH HHS
Grant: L30 HL170306
NHLBI NIH HHS
Grant: L30 HL159413
National Institutes of Health
Grant: 1R01HL168059-01
Pathogenic hotspots illuminate mechanism and therapeutic potential in arrhythmogenic cardiomyopathy
National Institutes of Health
Grant: 1F32HL160067-01
A transcriptional network which governs smooth muscle transition is mediated by causal coronary artery disease gene PDGFD
National Institutes of Health
Grant: 5K08HL167699-02
ADAR mediated RNA editing is a causal mechanism in coronary artery disease
National Institutes of Health
Grant: 5K08HL143185-03
The Role of RBM20 Sequence and Expression in Dilated Cardiomyopathies
FWCI
4.71
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals